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Endocrine therapy resistance invariably develops in advanced estro-
gen receptor-positive (ER+) breast cancer, but the underlying mech-
anisms are largely unknown. We have identified C-terminal SRC
kinase (CSK) as a critical node in a previously unappreciated negative
feedback loop that limits the efficacy of current ER-targeted thera-
pies. Estrogen directly drives CSK expression in ER+ breast cancer. At
low CSK levels, as is the case in patients with ER+ breast cancer
resistant to endocrine therapy and with the poorest outcomes, the
p21 protein-activated kinase 2 (PAK2) becomes activated and drives
estrogen-independent growth. PAK2 overexpression is also associ-
ated with endocrine therapy resistance and worse clinical outcome,
and the combination of a PAK2 inhibitor with an ER antagonist syn-
ergistically suppressed breast tumor growth. Clinical approaches to
endocrine therapy-resistant breast cancer must overcome the loss of
this estrogen-induced negative feedback loop that normally con-
strains the growth of ER+ tumors.
breast cancer | endocrine resistance | estrogen receptor |
CRISPR screen | CSK
Oncogenic activation of the estrogen receptor (ER) signalingpathway occurs in over 70% of breast cancers (1). This
forms the basis of endocrine therapy that employs antiestrogens
and aromatase inhibitors for both breast cancer prevention and
treatment (2). However, most patients with advanced disease
eventually develop resistance to these endocrine therapies, and
even for patients treated in the adjuvant setting, there is a con-
sistent risk of relapse that persists indefinitely (3). Notably, ap-
proximate 50% of patients with locally advanced or metastatic
ER+ breast cancer do not respond to first-line endocrine treat-
ment because of primary, de novo resistance (4). In addition,
most patients who initially respond to the therapy eventually
develop secondary acquired resistance (5). Despite significant
research efforts and discoveries made in recent years, the pre-
cise reasons for endocrine therapy failure in patients with ER+
breast cancer remain largely unknown. Published studies have
implicated increased expression of ER; mutations in the ESR1
gene; and activated growth factor receptor signaling, especially
of the EGFR/HER2 pathway, as important mechanisms of de
novo or acquired resistance (6–8). This has led to various tar-
geted combination strategies aiming to combat endocrine re-
sistance (3). For example, recent clinical trials have shown that
cotargeting the ER pathway with either the PI3K/Akt/mam-
malian target of rapamycin pathway or with the CDK4/6 in-
hibitor significantly improved the progression-free survival of
patients with ER+ breast cancer compared with endocrine
therapy alone (9–11).
Although clinical trials of combining other treatments with en-
docrine therapy are ongoing (12), the current choice of combina-
tion has been limited to existing therapies in breast cancer.
Furthermore, how the downstream oncogenic pathways of ER and
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growth factors are activated during endocrine therapy and whether
there are other intrinsic mechanisms limiting the efficacy of current
therapies remain to be elucidated. Therefore, systematic studies to
uncover synthetic lethal vulnerabilities and synergistic targets with
endocrine therapy are crucial for identifying novel and optimal
combination therapies. In addition, biomarkers predictive of clin-
ical response and molecular mechanisms underlying resistance to
endocrine therapies are critical for developing better therapeutic
strategies and improving patient outcome.
The recent introduction of the clustered, regularly interspaced,
short palindromic repeat (CRISPR)-associated nuclease Cas9
system has facilitated pooled loss-of-function genetic screens (13–
16). Seminal studies demonstrated the power of CRISPR screens
in identifying key genes or biomarkers that mediate drug and toxin
resistance (14, 17), immune response (18–21), and tumor metas-
tasis (22). This approach has also shown great promise in identi-
fying synthetic lethal interactions and revealing novel combination
therapies for precision cancer medicine (23, 24).
In this study, we conducted genome-wide CRISPR knockout
screens on two ER+ breast cancer cell lines to identify key medi-
ators of endocrine resistance. Based on the top tumor sup-
pressor gene identified in the primary screen whose loss
induced endocrine therapy resistance, we performed genome-
wide synthetic lethal CRISPR screens to discover novel tar-
gets for treating endocrine resistance. The gene signature
revealed by the CRISPR screen hits is associated with the
response to endocrine therapy in numerous clinical studies.
Finally, we validated combining endocrine therapy with inhibit-
ing a novel target identified in the synthetic lethal screen to
overcome endocrine resistance in cell line and patient-derived
tumor xenograft models. Our approach of utilizing a second
round of CRISPR screens to identify novel therapeutic tar-
gets provides an efficient alternative to conducting primary
CRISPR screens on large cell line panels to infer synthetic
lethal interactions.
Results
Genome-Wide CRISPR Screens Identified ER+ Breast Cancer-Specific
Essential Genes. To systematically investigate genes whose loss af-
fects cell viability or potentiates the estrogen-independent growth
of ER+ breast cancer cells, we performed genome-wide CRISPR/
Cas9 knockout screens in the ER+ breast cancer cell lines
MCF7 and T47D using the Genome-Scale CRISPR Knock-Out
(GeCKO) v2 library (25). After infection with the lentiviral guide
RNA (gRNA) library and selection by puromycin, the cells were
cultured in hormone-depleted medium and treated with either
estrogen (17β estradiol or E2) or vehicle (Veh) control over 4 wk
(Fig. 1A). The sequences encoding the gRNA were PCR-amplified
from the transduced cells at day 0 and after 4 wk of culture and
quantified by high-throughput sequencing (SI Appendix, Fig. S1 A
and B). We then identified negatively and positively selected genes
by calculating the gene essentiality score using MAGeCK-VISPR,
a statistical algorithm we previously developed for CRISPR screen
analyses (26, 27). The MAGeCK-VISPR algorithm compares the
gRNA abundance of all of the gRNAs targeting a gene across
different conditions and assigns each gene a log fold-change
“β-score” of essentiality in each condition compared with the
controls. A positive (or negative) β-score indicates the corre-
sponding gene is under positive (or negative) selection in the
CRISPR screen (Dataset S1). Overall, most genes are consistently
positively or negatively selected across conditions and cell lines
(Fig. 1B). Known driver genes for ER+ breast cancers (28, 29),
such as ER (ESR1) itself, GATA3, FOXA1, and MYC, are
strongly negatively selected (Fig. 1 B and C), while tumor sup-
pressors, such as NF1, TSC1, TSC2, and PTEN, are positively
selected (Fig. 1B). The essential genes are enriched in many
fundamental biological processes, such as gene expression, RNA
processing, and translation (Fig. 1C and SI Appendix, Fig. S1C). In
addition, ER and its signaling network genes (MYC, FOXA1,
CCND1, PHB2, NCOA3, and AKT1) remain essential in the Veh
condition (SI Appendix, Fig. S1D), and the top essential genes
significantly overlap between the E2 and Veh conditions (Fisher’s
exact test: P < 2.2e-16; SI Appendix, Fig. S1E and Dataset S2).
These data indicate that the ER pathway continues to play an
essential role even in the absence of estrogen.
We next sought to identify genes with a stronger negative se-
lection in ER+ breast cancer cells compared with other cancer
cells, as they may be the therapeutic targets for breast cancer.
We collected public genome-wide CRISPR screen data from 43
cell lines representing 13 different cell types (14, 16, 30, 31) and
compared them with the screening results on T47D and MCF7
(under E2 treatment). We derived a score to quantify whether
a gene is ER+ breast cancer-specific essential by comparing this
gene with other genes within the same cell line and the same
gene in other cancer cells (details are provided in Materials and
Methods). This approach identified ∼176 genes with specific es-
sentiality in ER+ breast cancers [false discovery rate (FDR) ≤
0.1; Fig. 1 D and E and Dataset S3]. Overall, the ER+ breast
cancer-specific essential genes tend to have higher expression in
T47D and MCF7 cells compared with the other cell lines (Fig.
1F), are amplified or up-regulated in samples from patients with
breast cancer (SI Appendix, Fig. S1F), and are enriched in breast
cancer-related pathways (Dataset S4). Many of these genes have
physical or genetic interactions with ER (SI Appendix, Fig. S1G),
confirming the central role of ER in ER+ breast cancer cells.
Interestingly, seven of the top 20 specific essential genes are
transcription factors (GATA3, TFAP2C, TRPS1, FOXA1,
ESR1, SPDEF, and GRHL2). Among these, FOXA1, GATA3,
SPDEF, and TFAP2C are known to interact with ER and exert
critical functions in breast cancer (32–35). TRPS1 and GRHL2
are also associated with breast cancer progression and have been
implicated as oncogenes in ER+ breast cancers (36–38) (SI Ap-
pendix, Fig. S1H). The identification of ER and the known
components of the ER signaling pathway, as well as other pre-
viously identified breast cancer oncogenes, validated the robust
nature of the screen.
Loss of C-Terminal SRC Kinase Mediates Estrogen-Independent
Growth of ER+ Breast Cancer Cells. We next searched for key
genes that drive estrogen-independent growth by finding genes
with stronger positive selection in the Veh condition compared
with the E2 condition (Fig. 2A). The hit list (Dataset S5) includes
several known tumor suppressor genes, including NF2, TSC2,
LATS2, and PTEN, as well as NF1, whose silencing has been
previously reported to cause tamoxifen resistance (39). The
strongest differential hit in both T47D and MCF7 cells is C-
terminal SRC kinase (CSK) (Fig. 2A and SI Appendix, Fig.
S2A). CSK has been previously implicated to be involved in
fulvestrant-induced cell death in MCF7 cells, yet through a
mechanism independent of SRC family kinases (SFKs) (40). All
six CSK-targeting gRNAs in the GeCKO2 library are dramati-
cally enriched in both MCF7 and T47D cells in the Veh versus
E2 condition (SI Appendix, Fig. S2B). Interestingly, CSK was not
found to be positively selected in recent genome-wide shRNA
screens of ER+ breast cancer cells cultured in full medium (41) (SI
Appendix, Fig. S2C). Given that CSK was the top positively selected
gene in both MCF7 and T47D cell lines in estrogen-depleted
medium and its known role in inhibiting the function of SFKs
(42), we focused on CSK for further analysis.
We first sought to validate that CSK knockout confers E2-
independent growth of ER+ breast cancer cells. We introduced
three different gRNAs targeting CSK (one from the GeCKO2
library and two newly designed) and a control gRNA targeting
the AAVS1 safe-harbor locus into T47D and MCF7. All three
CSK-targeting gRNAs depleted CSK protein and markedly
stimulated cell growth in stripped medium without E2 (Fig. 2B),
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but they had only marginal growth effects in full medium or in
stripped medium plus E2 (SI Appendix, Fig. S2D), indicating
CSK loss is a specific driver for E2-independent growth of these
cells. The same phenotype was also observed in two additional
ER+ breast cancer cell lines, ZR75-1 and HCC1428 (Fig. 2C).
Extending our cell culture findings in vivo, we also confirmed
that depletion of CSK resulted in E2-independent growth of
MCF7 xenografts in ovariectomized mice (Fig. 2D). In contrast to
the AAVS1-targeted control MCF7 xenografts that showed al-
most complete dependence on E2 for growth, the CSK-depleted
MCF7 xenografts grew robustly in the absence of E2 and were
only modestly stimulated by the addition of E2. Moreover, de-
letion of CSK induced a striking sickle-like morphology in both
T47D and MCF7 cells and increased cell migration in a transwell
assay (SI Appendix, Fig. S2 E and F), suggesting a more motile
phenotype (43). Finally, the estrogen-independent growth and
morphological changes in these CSK-null cells could be fully re-
versed by the overexpression of a human CSK cDNA containing
protospacer adjacent motif sequence mutations in each of the
targets of the three CSK gRNAs to escape CRISPR/Cas9 cutting
(Fig. 2B and SI Appendix, Fig. S2E).
CSK Is Directly Regulated by ER. As CSK was differentially selected
between the Veh and E2 conditions, we next asked whether es-
trogen and ER regulated CSK expression. The expression of CSK
is up-regulated in a majority of breast cancer cell lines or mouse
models treated with E2 in the Nuclear Receptor Signaling Atlas
database (44) (SI Appendix, Fig. S3A). Examination of ER and
H3K27ac ChIP-sequencing (ChIP-seq) and DNase-sequencing
data revealed a putative ER-bound enhancer ∼10 kb upstream
of the CSK transcription start site (Fig. 3A). This region contains
an ER-binding site as well as an ER-binding motif, and it is largely
marked by H3K27ac only in ER+ breast cancer cell lines, sug-
gesting that it is an ER-specific enhancer (SI Appendix, Fig. S3B).
In 86% (19 of 22) of patients with ER+ breast cancer, ER was
bound to the enhancer of CSK, while in two patients with ER−
breast cancer, no ER binding was detected (45) (SI Appendix, Fig.
S3C), an indication that the ER-CSK regulation may be wide-
spread in ER+ breast tumors. To test whether ER activates CSK
through this putative enhancer, we introduced three pairs of
gRNAs together with Cas9 to fully or partially delete the putative
enhancer and another pair targeting a region away from the en-
hancer as a control (Fig. 3B). In the absence of Cas9/gRNA
transfection, CSK expression is strongly up-regulated upon E2
treatment. This activation was abrogated when the enhancer was
disrupted, while deletion of a nearby region did not affect CSK
expression (Fig. 3C and SI Appendix, Fig. S3D). Moreover, the
deleted enhancer, but not the nearby region, confers hormone-
independent growth of the cells, indicating that this enhancer is
required both for the ER regulation of CSK and for the sup-
pression of estrogen-stimulated growth (SI Appendix, Fig. S3E).
Changes in Growth Factor Signaling upon CSK Loss Mediate Endocrine
Resistance in ER+ Breast Cancer Cells. To understand how CSK loss
leads to estrogen-independent growth of ER+ breast cancer cells,
we performed RNA-seq analysis to identify differentially expressed
genes and pathways upon CSK loss in T47D and MCF7 cells.
Loss of CSK led to global changes in gene expression (SI Ap-
pendix, Fig. S4A and Dataset S6), and we defined a signature of
292 CSK-suppressed genes consistently up-regulated upon CSK
knockout in both MCF7 and T47D (log2 fold change > 1 and
adjusted P < 0.01; SI Appendix, Fig. S4C and Dataset S7). The
expression of EGFR, whose overexpression can elicit tamoxifen
resistance (1), was significantly increased after CSK loss (SI Ap-
pendix, Fig. S4A). In addition, EGFR signature genes, genes asso-
ciated with high-grade ER+ breast tumors as well as other oncogenic
pathways, such as metastasis, cell cycle, and epithelial-mesenchymal
transition, were significantly up-regulated (Fig. 4A and SI Appendix,
Fig. S4B and Dataset S7). These results suggest that CSK deletion
or expression suppression activates growth factor signaling pathways,
which could drive the E2-independent growth of ER+ breast cancer
cells and elevate breast tumor grade. Partial or complete ablation of
ER significantly decreased cell proliferation in both MCF7 and
T47D CSK-null cells (SI Appendix, Fig. S4D), suggesting that ER
continues to play an important role in the absence of CSK. Given
the essential role of ER in CSK-null cells, we tested whether the
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Fig. 1. CRISPR functional screens on two breast cancer cell lines, T47D and
MCF7. (A) Outline of the genome-wide CRISPR screen strategy. (B) Positively
selected (red) and negatively selected (blue) genes in T47D and MCF7 cells
under E2 (10 nM) and Veh (EtOH) treatments in hormone-depleted medium
plus 10% dextran-charcoal–treated FBS. The positive (or negative) β values
(calculated from the MAGeCK algorithm) indicate positive (or negative) se-
lection of a gene, respectively. (C) Network view of top 1,000 negatively
selected genes in T47D and MCF7. Here, nodes represent genes and an edge
connecting two genes if both are in the same pathway. ER and its associated
genes are highlighted in red. The pathway information is extracted from the
GeneMANIA database (69). Six hundred seventy-one unconnected genes are
not shown. (D) Scores of breast cancer-specific essential genes. The names
and ranks of some known breast cancer-specific genes are marked. The score
is based on the screening data of T47D and MCF7 (under E2 treatment), as
well as other cell lines collected from public CRISPR screens. (E) β-Scores of
breast cancer-specific essential genes in multiple cancer cell types. (F) Expres-
sion of breast cancer-specific essential genes is significantly higher in breast
cancer cell lines than in other cell lines (Wilcoxon rank-sum test: *P < 0.05).
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growth of CSK-null T47D or MCF7 cells could be inhibited by ta-
moxifen or fulvestrant. Notably, the CSK-null T47D or MCF7 cells
were completely resistant to the ER antagonist tamoxifen but
retained partial sensitivity to the ER degrader fulvestrant (Fig. 4B).
We observed that loss of CSK only partially inhibits the ability of
fulvestrant to degrade ER (SI Appendix, Fig. S4E), consistent with a
previous study showing activated SFKs blocking fulvestrant-induced
ER down-regulation (46). Additionally, we have previously dem-
onstrated that while tamoxifen is unable to prevent growth factor-
stimulated ER signaling, fulvestrant is able to more fully inhibit ER
action (47). These results demonstrate that ER remains essential for
estrogen-independent growth induced by CSK loss.
Genome-Wide CRISPR Screen for Genes Synthetically Lethal with CSK
Loss. To identify the key genes that drive hormone-independent
growth upon CSK loss, we performed a second round of genome-
wide CRISPR screening in the CSK-null T47D cells and control
cells cultured in hormone-depleted medium treated with E2 or
Veh (SI Appendix, Fig. S5 A–C and Dataset S8). Using the same
approach to compare public screening datasets of non-breast
cancer cell lines, we identified 685 specific essential genes in
CSK-null T47D cells under Veh treatment with statistical signifi-
cance (FDR ≤ 0.05; Dataset S9). These genes include genes in the
HER2 (ERBB2), PI3K-AKT (PIK3R1/2, AKT1), and MAPK
signaling pathways [MAPK8, p21 protein-activated kinase 2
(PAK2)] that are known to be activated in endocrine-resistant
breast tumors (1) (Fig. 5A). Of note, ER remains essential in the
absence of CSK, albeit to a lesser extent compared with the control
cells (β = −0.43 and −0.28, ranking = 23 and 629 in the control and
CSK-null cells, respectively). The essentiality of ER and genes in
the HER2/EGFR signaling pathway in the CSK-null cells is further
supported by the up-regulated ER and EGFR signature genes in
the CSK-null cells (Fig. 4A and SI Appendix, Fig. S4A). These
results suggest that loss of CSK increases cross-talk between ER
and growth factor signaling pathways.
We next sought to identify genes that are specifically essential in
the CSK-null cells under the Veh condition, as these would be the
key genes that are suppressed by CSK and confer endocrine re-
sistance in the cells upon CSK loss. Applying the same MAGeCK-
VISPR method to compare screening results between the control
and CSK-null T47D cells, we discovered over 60 genes that are
not required in control cells under the E2 condition but are spe-
cifically required in the CSK-null cells under the Veh condition
(Dataset S10). Several top hits, such as EPHB2, proto-oncogene
c-crk (CRK), PAK2, and PIK3R2, are in SFK pathways (Fig. 5A).
However, none of the nine SFK members could be identified as an
essential gene in the CSK-null cells (Fig. 5B), indicating that
paralogs of the SFKs may provide functional redundancy (30).
Two particularly interesting genes, PAK2 and CRK, are directly
associated with SFK signaling pathways (Fig. 5C). PAK2 is a ser-
ine/threonine kinase whose activity can be stimulated by the small
GTPases CDC42 and RAC1 (48) and regulated by the SFKs
-
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Fig. 2. CSK mediates hormone-independent breast cancer cell growth. (A) Top positively selected genes in both T47D and MCF7 cells cultured in hormone-
depleted medium plus 10% dextran-charcoal–treated FBS (DCC-FBS) treated with Veh (EtOH) conditions, compared with E2 (10 nM) conditions. The RRA
scores obtained by comparing Veh versus E2 conditions from MAGeCK are shown. (B, Left) Effects of cell growth by knocking out CSK in T47D and MCF7 cells
using three different gRNAs against CSK and one AAVS1_gRNA as a control. The CSK function was rescued by the expression of three gRNA-resistant CSK
cDNAs in these CSK-null cells. Cell growth was measured by crystal violet staining assays, and the cells were cultured in hormone-depleted medium plus 10%
DCC-FBS. (B, Right) Immunoblot analysis for indicated proteins of control (gAAVS1), CSK-null, and rescued CSK-null cells. GAPDH was used as a loading
control. (C, Left and Center) Estrogen-independent growth of ZR75-1 and HCC1428 cells harboring two different gRNAs against CSK and one gAAVS1 as a
control. All of the cells were cultured in hormone-depleted medium plus 10% DCC-FBS. The data are represented as mean ± SD (n = 3; two-tailed Student’s
t test: *P < 0.05, **P < 0.005). (C, Right) Immunoblot analysis for indicated proteins of control (gAAVS1) and CSK-null cells. GAPDH was used as a loading
control. (D) Estrogen-independent growth of MCF7 xenografts. MCF7 cells harboring either gAAVS1 or gCSK were injected into the ovariectomized nude mice
in the presence of estrogen. Mice were assigned randomly (day 7), in groups of eight, to continued estrogen supplementation (E2, 0.1 mg·kg−1·wk−1) or
estrogen withdrawal (−E2). Luminescence values were plotted as an average of percentage of the first measurement (% relative bioluminescence) for each
mouse in each respective group. The measurements were performed in intact male mice at days 10, 17, 25, 31, and 37 after tumor cell injection (two-tailed
Student’s t test: *P < 0.05, **P < 0.005).
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(49, 50). CRK is a member of an adapter protein family that binds
to several tyrosine-phosphorylated proteins and is involved in ac-
tivating SFKs (51). We focused on PAK2 among the top synthetic
lethal candidates of CSK as it is highly expressed in ER+ breast
cancer cells and it is a potential therapeutic target with existing
small-molecule inhibitors. To confirm the specific requirement of
PAK2 in the CSK-null cells, we knocked out PAK2 in the CSK-
null cells and control cells using three different gRNAs targeting
PAK2 (Fig. 5D). Consistent with our screen data, PAK2 (but not
PAK1) is essential only in the CSK-null cells cultured under the
Veh condition (SI Appendix, Fig. S5D), and the degree of PAK2
essentiality is correlated with the knockout efficiency (Fig. 5D).
This synthetic lethal interaction between PAK2 and CSK is also
observed in three additional ER+ breast cancer cells (MCF7,
ZR75-1, and HCC1428; SI Appendix, Fig. S5E), supporting its
general importance in ER+ breast tumors. In addition, the cell
growth inhibition in the CSK-null cells upon PAK2 loss could be
rescued by the doxycycline-inducible overexpression of a gPAK2/
Cas9-resistant WT PAK2 cDNA (Fig. 5E), confirming the essential
role of PAK2 in hormone-independent cells induced by CSK loss.
To further understand how CSK loss leads to PAK2 activation,
we investigated the phosphorylation patterns of PAK2 and SFKs.
The autophosphorylation site (Serine141) of PAK2, an impor-
tant marker of PAK2 activation (52), could be distinctly detected
in the CSK-null cells but not in the control or CSK-rescued cells
(Fig. 5F). More importantly, this differential phosphorylation
pattern of PAK2 is correlated with the differential phosphory-
lation pattern of the SFKs (Fig. 5F), suggesting that PAK2 and
SFKs could be simultaneously activated upon CSK loss. To un-
derstand whether the activation of PAK2 is SFK-dependent, we
treated the CSK-null cells with two SFK inhibitors, dasatinib and
saracatinib. The phosphorylation of PAK2 S141 was abrogated
upon the inhibitor treatment (Fig. 5G), suggesting that SFKs are
involved in PAK2 activation by tyrosine phosphorylation. To un-
cover the specific tyrosine on PAK2 that is important for PAK2
function, we generated three Y-to-F mutations (Y130F, Y139F,
and Y194F) in PAK2 that have been previously implicated in
PAK2 function (49). As PAK2 is essential in the CSK-null cells,
we first transduced the CSK null cells with PAK2-encoding len-
tiviruses to allow inducible overexpression of WT PAK2 and the
PAK2 mutants. The endogenous PAK2 was then deleted using a
specific gRNA, and the cell viability was assayed in the presence
or absence of the inducible PAK2 alleles. While the Y139F and
Y194F mutants could rescue PAK2 function to similar levels as
WT PAK2, the Y130F mutant failed to rescue PAK2 function
(Fig. 5E), indicating the critical role of Y130 in SFK-mediated
phosphorylation and activation of PAK2.
An Estrogen-Regulated Feedback Loop Limits the Effectiveness of
Current Endocrine Therapy. As CSK expression in ER+ breast
cancer cells is induced by estrogen, we next asked whether en-
docrine therapy inhibited CSK expression in these cells. Treatment
of MCF7 cells with tamoxifen or fulvestrant for 2, 4, and
6 d gradually decreased CSK protein expression and induced
activating phosphorylation of SFKs and PAK2 (SI Appendix, Fig.
S6A). This supports the existence of a negative feedback loop,
where endocrine therapies that inhibit ER activity repress CSK
expression and activate SFKs and PAK2. In addition, CSK ex-
pression is decreased in other models of endocrine resistance,
including long-term estradiol-deprived (LTED) and tamoxifen-
or fulvestrant-resistant cell lines (SI Appendix, Fig. S6B). To in-
vestigate the clinical relevance of CSK inhibition as a mechanism
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Fig. 4. Growth factor and ER signaling changes induced by CSK loss. (A)
Gene set enrichment analysis for EGFR signature genes and genes associated
with higher grade (grade 3) ER+ breast tumors. The corresponding gene set IDs in the
Molecular Signatures Database (70) are “KOBAYASHI_EGFR_SIGNALING_24HR_DN”
and “SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP,” respectively. Genes in
the figures (black bars) are ranked based on their differential expression be-
tween CSK-null and control cells. (B) Effects of CSK knockout on sensitivity to
two ER antagonists, tamoxifen and fulvestrant, in T47D and MCF7 cells. The
relative cell viability of control (AAVS1) and CSK-null cells after treatment with
indicated compound concentrations for 5 d is shown (mean ± SD for n = 3;
two-tailed Student’s t test: *P < 0.05, **P < 0.005). All of the cells were
cultured in full medium (DMEM or RPMI 1640) with 10% FBS.
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Fig. 3. ER binds to CSK enhancer and regulates CSK expression. (A) ER ChIP-
seq, as well as DNA hypersensitivity (DNase-I) and H3K27ac signals on the
proximal enhancer region of CSK. (B) Zoomed-in view of the enhancer re-
gions upstream of CSK. The positions of six gRNAs targeting this putative
enhancer are also shown. (C) Knockout of the ER-binding site and its
flanking region by four pairs of gRNAs against these regions. After hormone
depletion for 2 d, the cells were treated with E2 (40 nM) for the indicated
times and total RNA was subjected to real-time RT-PCR analysis to measure
the mRNA level. The relative gene expression was measured by qRT-PCR
after normalizing to the amount of GAPDH signal (mean ± SD for n = 3;
two-tailed Student’s t test: *P < 0.05, **P < 0.005).
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Fig. 5. PAK2 is synthetic lethal to CSK loss. (A) Essentialities of genes in the SFKs and associated pathways, measured by β-scores from CRISPR screens, in CSK-
null cells. Genes are colored based on their β-scores. (B) β-Scores in CSK-null cells versus CSK WT cells. Two Src pathway genes (PAK2 and CRK) and SFKs are
marked. (C) Interaction network of genes that are differentially required upon CSK loss. Edges connecting genes indicate possible gene interactions from
public datasets. (D) Validation of a synthetic lethal interaction between PAK2 and CSK in T47D cells. Relative viabilities of T47D CSK-null (gCSK3) and control
(gAAVS1) cells harboring three gRNAs against PAK2 and one gAAVS1 as a control are shown (mean ± SD for n = 3; two-tailed Student’s t test: *P < 0.05, **P <
0.005). N.S., not significant. The control cells were cultured in hormone-depleted medium [10% dextran-charcoal–treated FBS (DCC-FBS)] plus E2 (10 nM), and
the CSK-null cells were cultured in hormone-depleted medium (10% DCC-FBS) plus Veh. Immunoblot analysis indicated the protein level of PAK2 and CSK in
the control (AAVS1) and CSK-null T47D cells. GAPDH was used as a loading control. (E) Rescue assay for PAK2 function. Relative viabilities of T47D WT (ctrl)
cells, as well as CSK and PAK2 double-KO cells with inducibly rescued WT PAK2 and PAK2 mutants (Y130F, Y139F, and Y194F) are shown [“+” and “−” indicate
plus/minus doxycycline (1 μg/mL) treatments respectively]. The T47D CSK-null cells were first transduced with PAK2-encoding lentiviruses to allow inducible
overexpression of WT PAK2 and the PAK2 mutants. The endogenous PAK2 was then deleted using the specific gRNA (gPAK2_3) without affecting the ex-
ogenous PAK2 (mean ± SD for n = 3; **P < 0.005). All of the cells were cultured in hormone-depleted medium plus 10% DCC-FBS, and GAPDH was used as a
loading control. (F) Immunoblot analysis indicated the protein level of phosphorylated PAK2 and SFK as well as the total protein level of CSK, SFK, and PAK2
in the control (gAAVS1), CSK-null, and rescued CSK-null T47D cells. (G) Expression of PAK2 and PAK2S141 upon treatment with two SFK inhibitors, dasatinib
and saracatinib, in the CSK-null cells for 1, 3, and 6 h. ctrl, CSK-null cells with Veh treatment for 6 h. All of the cells were cultured in hormone-depleted
medium plus 10% DCC-FBS, and GAPDH was used as a loading control.
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of endocrine therapy resistance, we obtained 47 matched pairs of
primary and tamoxifen-resistant tumor samples and found CSK
to be down-regulated in 64% (30 of 47) of the tamoxifen-resistant
tumors by immunohistochemistry (Fig. 6A). These data suggest
that down-regulation of CSK may be a frequent mechanism of
acquired endocrine resistance.
To further support the clinical importance of CSK inhibition
for endocrine resistance in ER+ breast cancers, we collected
public datasets of patients with breast cancer treated with en-
docrine therapy and linked the gene expression data with clinical
outcome (Fig. 6 C and D). As CSK is very highly expressed in
lymphoid tissues (SI Appendix, Fig. S6C), its expression in tumors
may be biased by the presence of tumor infiltrating lymphocytes.
We thus used the increased expression of the 292 CSK-
suppressed signature genes as a proxy for CSK inhibition (SI
Appendix, Fig. S4C). The expressions of the signature genes are
negatively correlated with CSK expression across different tissue
types (SI Appendix, Fig. S6 D and E), providing a reliable proxy
for estimation of CSK activity in tumor samples. In two clinical
trials that include breast tumor expression measurements before/
after endocrine therapy (53, 54), tumors with the CSK inhibition
signature show significantly less Ki67 reduction upon treatment,
indicating that endocrine therapy is less effective in these pa-
tients (Fig. 6B). In four additional studies (55–59) of patients
treated with tamoxifen, the CSK inhibition signature is signifi-
cantly correlated with high-grade ER+ tumors and worse survival
(Fig. 6C and SI Appendix, Fig. S6F). Moreover, higher expression
of PAK2 in these cohorts is also significantly associated with
worse clinical outcome after tamoxifen treatment (Fig. 6D).
These data support the clinical importance of the negative
feedback loop, whereby endocrine therapies inhibit expression of
CSK, leading to activation of PAK2, ultimately limiting the ef-
fectiveness of the therapy.
Potential Therapeutic Strategies to Overcome Endocrine Resistance.
Given the existence of the ER-regulated negative feedback loop
involving CSK inhibition and PAK2 activation that limits the
effectiveness of endocrine therapy and contributes to endocrine
resistance of ER+ breast cancer cells, we tested the effect of si-
multaneously inhibiting ER and PAK2. Combining the PAK2
inhibitor FRAX597 with fulvestrant or tamoxifen showed strong
synergy in both MCF7 CSK-null cells and WT MCF7 cells (SI
Appendix, Fig. S7A). To test PAK2 as a potential therapeutic
target in endocrine-resistant breast cancer, we treated the
endocrine-resistant, CSK-null xenograft tumors in ovariecto-
mized mice with FRAX597. Tumors were more sensitive to
PAK2 inhibition in the absence of E2 (Fig. 7 A and B), sug-
gesting the CSK–PAK2 synthetic lethal interaction was more
pronounced in hormone-deprived conditions. While fulvestrant
alone inhibits the growth of CSK-null tumors to some extent, the
combination of fulvestrant with FRAX597 is substantially more
effective in blocking the growth of CSK-null tumors with or
without E2 (Fig. 7B). We further tested the efficacy of combining
FRAX597 with fulvestrant in an ER+ patient-derived xenograft
(PDX) model of breast cancer (TM00386; The Jackson Labo-
ratory). While treatment with FRAX597 or fulvestrant alone
reduces tumor growth, the combination was synergistic and
completely inhibited tumor growth (Fig. 7C and SI Appendix,
Fig. S7 B and C). The individual and combined treatments were
very well tolerated, as we observed consistent weight gain among
the mice on the various treatment arms of the study (SI Ap-
pendix, Fig. S7D). These data suggest dual PAK2 and ER in-
hibition as an effective combination therapy for treating ER+
breast cancer.
Discussion
Using genome-wide CRISPR/Cas9 screening, we identified es-
sential genes driving the growth of ER+ breast cancer cells, in-
cluding many transcription factors that are key components of
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Fig. 6. Clinical relevance of an ER-regulated feed-
back loop. (A) Illustrated images of CSK staining
(immunohistochemistry) in matched primary and
tamoxifen-resistant (TamR) ER+ breast tumors (Scale
bar: 100 μm.). Quantification distribution of CSK
staining in 47 matched pairs is shown, including 30
(or 12) that have decreased (or increased) CSK ex-
pression at the TamR stage, respectively. The P value
is calculated using a two-tailed paired Student’s
t test. (B) CSK gene signatures predict patient re-
sponse to endocrine treatments in two endocrine
treatment clinical trials that have matched expres-
sion measurements before and after treatment (53,
54). Patients in the “High CSK-supp. sig. exp” group
(or patients with high expression of CSK-suppressed
signature genes as a surrogate of CSK loss after
treatment) have less reduction of Ki67 gene expres-
sion, an indication of less efficacy in endocrine
treatment. The P value is calculated using the Wil-
coxon rank-sum test. More details are provided in
Materials and Methods. (C) Higher expression of
CSK-suppressed signature genes (High CSK-supp. sig.
exp) indicates worse clinical outcome in four ex-
pression datasets of patients with breast cancer who
were treated with tamoxifen (55–59). Expression
data are extracted and processed from the National
Center for Biotechnology Information Gene Expres-
sion Omnibus under the accession number shown in
each figure, respectively. (D) PAK2 overexpression
corresponds to worse clinical outcome in a cohort of
patients with breast cancer who were treated with
tamoxifen.
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the estrogen signaling pathway. More significantly, these screens
revealed a previously unappreciated negative feedback loop that
limits the efficacy of ER-targeted therapies and, when disrupted,
leads to endocrine resistance (Fig. 7D). We found CSK to be a key
component of this feedback loop and an estrogen-stimulated tu-
mor suppressor whose loss drives hormone-independent cell
growth. From a secondary genome-wide CRISPR/Cas9 screen, we
uncovered a synthetic lethal interaction between CSK and PAK2
in endocrine-resistant breast cancer cells. In the presence of es-
trogen, ER activates CSK, whose expression represses SFK and
PAK2 activity. Inhibition of ER activity by endocrine therapy re-
presses CSK, allowing the activation of SFK and PAK2 indepen-
dent of ER regulation. Activation of SFK and PAK2, in turn,
stimulates oncogenic signaling pathways and promotes estrogen-
independent growth. While the continued requirement for ER
genomic action upon CSK depletion is supported by the finding of
the up-regulation of direct ER target genes in the CSK-null cells
versus the control cells in estrogen-depleted medium, we cannot
rule out a contribution of nongenomic ER signaling as well.
Our preclinical results both in vitro and in vivo, combined with
clinical observations of the impact of CSK loss and PAK2 over-
expression on patient survival, strongly support the clinical impor-
tance of this negative feedback loop. Our data also suggest PAK2 as
a therapeutic target in patients with ER+ breast cancer, both after
the development of endocrine resistance and potentially in hormone-
sensitive patients, to increase the efficacy of ER-targeted therapy.
Materials and Methods
Breast Cancer Cell Culture. The MCF-7, T47D, ZR75-1, and HCC1428 human cell
lines were grown as described previously (60). Tam-R and Flu-R cells were
derived by long-term exposure to tamoxifen and fulvestrant grown under the
same conditions as WT MCF-7 and T47D cells (61). T47D/LTED and MCF-7/LTED
cells were generated through culture in phenol red-free RPMI 1640 and
DMEM supplemented with 10% dextran-charcoal–treated FBS (HyClone) (62).
Computational Analysis of the Screens. The CRISPR/Cas9 screening data are
processed and analyzed using theMAGeCK andMAGeCK-VISPR algorithmswe
previously developed (26, 27). We use the MAGeCK-VISPR algorithm (27) to
compare the gene selections across different conditions and different studies
(Fig. 1E), as well as the specific essential genes in CSK-null cells (Dataset S9).
The MAGeCK-VISPR algorithm uses a metric β-score to measure gene selec-
tions. The definition of the β-score is similar to the term “log fold change” in
differential expression analysis, and β > 0 (or β < 0) means the corresponding
gene is positively (or negatively) selected, respectively. MAGeCK-VISPR models
the gRNA read counts as a negative binomial (NB) variable, whose mean value
is determined by the sequencing depth of the sample, the efficiency of the
gRNA, and a linear combination of β-scores of the genes. MAGeCK-VISPR then
builds a maximum likelihood (MLE) model to model all gRNA read counts of
all samples and iteratively estimate the gRNA efficiency and gene β-scores
using the expectation-maximization algorithm. A detailed description of the
MAGeCK-MLE algorithm can be found in the original study (27).
To identify breast cancer-specific essential genes (Fig. 1E), we make use of
public genome-wide CRISPR screening datasets recently published (14, 16,
30, 31). The first dataset (16) includes screens of cells from colorectal carci-
noma (DLD1 and HCT116), patient-derived glioblastoma (GBM), cervical
carcinoma (HELA), and retinal epithelium (RPE1). The second dataset per-
forms screens on leukemia cell lines (KBM7, K562, JIYOYE, and RAJI) (30), the
third dataset is based on one melanoma cell line (A375), and the last dataset
includes CRISPR screening data of 33 cell lines from various cancer types (31).
For each dataset, we use the MAGeCK-VISPR algorithm to calculate the
β-scores of all genes. Breast cancer-specific essential genes are those that (i)
are negatively selected in breast cancer cell lines and (ii) have stronger
negative selection values in breast cancer cell lines compared with non-
breast cancer cell lines. Therefore, for each gene, we define its breast
cancer-specific essential score SEg as
SEg = logðrankðtsÞÞ+ logðrankðmeanðβBC ÞÞÞ,
where ts is the t-statistics tested on the β-scores of two groups [breast cancer
(BC) cells and non-BC cells] and rankð · Þ is the rank function (converted to
uniform distributed values between [0,1]). A lower SE score indicates this
gene is an essential gene in breast cancer cells [smaller meanðβBCÞ] and is
more essential in breast cancer cell lines compared with non-breast cancer
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Fig. 7. Potential therapeutic strategies to overcome endocrine resistance. (A) Representative images showing BILs in female, athymic, ovariectomized nude
mice plus/minus estrogen (0.1 mg·kg−1·wk−1) bearing MCF7 CSK-null tumors, which were treated with Veh, FRAX597(60 mg·kg−1·d−1), fulvestrant (5 mg·
wk−1), or combinations for 4 wk. (B) Effects of treatments on the CSK-null xenografts. Mice with CSK-null tumors were treated with single or combination
treatment with Veh, FRAX597, and fulvestant for 4 wk. Luminescence values were plotted as an average of percentage of the first measurement (% relative
BIL) for each mouse in each respective group (n = 8). P values were calculated by the Student’s t test. (C) Single or combination treatments with Veh, FRAX597,
and fulvestant in TM00386 PDX (The Jackson Laboratory) tumors for 35 d in each respective group (n = 8). P values are indicated from a two-tailed unpaired
t test. Data are represented as mean ± SD. (D) Proposed mechanism of endocrine resistance driven by CSK loss and synthetic lethal vulnerabilities with SFK and
PAK2 genes for ER+ breast cancer.
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cell lines (smaller ts). The P values are calculated from the null distribution of
rank product statistics as described before (63, 64). Multiple comparison cor-
rection of the P values is performed using the Benjamini–Hochberg method (65).
We use MAGeCK (26) to identify genes whose knockout leads to stronger
positive selection in Veh conditions compared with E2 conditions in T47D
and MCF7 cells (Fig. 2A). The MAGeCK algorithm works as follows. It first
collects read counts of all gRNAs in all conditions from fastq files, and then
normalizes the read counts of control and treatment conditions using me-
dian normalization. After that, MAGeCK builds a linear model to estimate
the variance of gRNA read counts, evaluate the gRNA abundance changes
between control and treatment conditions, and assign a P value using the
NB model. Finally, the selection of genes is evaluated from the rankings of
gRNAs (by their P values) using the α-robust rank aggregation (α-RRA) al-
gorithm. For each gene, α-RRA evaluates the rankings of all its gRNAs and
assigns a lower score (RRA score) if the distribution is more skewed com-
pared with a uniform distribution. The statistical significance of the RRA
score is evaluated by permutation, and the Benjamini–Hochberg method is
used for multiple comparison adjustments. To increase the statistical power,
genes that have fewer than four gRNAs or genes that have fewer than two
significant gRNAs are excluded from the comparison. A detailed description
of the MAGeCK algorithm can be found in the original study (26).
Cell Proliferation Assays. The breast cancer cells were plated in 24-well plates
(4–5 × 104 cells per well) and kept under indicated conditions. The cells were
trypsinized and collected. The number of viable cells was determined by
Trypan blue exclusion and directly counted using a hemocytometer. Data
represent mean ± SD from three independent replicates. P values were
calculated using an unpaired Student’s t test. ATP-based measurements of
cellular proliferation were performed by the CellTiter 96 Non-Radioactive
Cell Proliferation Assay (Promega). The cells were plated in 96-well plates
(4,000 cells per well) and biologically replicated three times.
Cell Viability Assays. The activity levels of single agents and combinations
were determined by the CellTiter 96 Non-Radioactive Cell Proliferation Assay.
The cells were seeded in 96-well plates (4,000 cells per well), cultured 18–24 h
before compound addition, and biologically replicated three times. Upon
addition of drug, cells were incubated for 5 d.
Cell Migration. The migratory ability of MCF-7 cells was assessed using a
transwell chamber (6.5-mm insert diameter, 8-μm pore size) (catalog no.
353097; Corning) placed in 24-well culture plates. Differently treated MCF-7
cells (5 × 104 per well) were suspended in 10% FBS DMEM and seeded to
the upper chambers of the transwell plates, and the lower chambers were filled
with 1 mL of DMEM containing 20% FBS. Following 36 h of incubation at 37 °C,
cells located on the upper membranes were removed with Q-tips, and the cells
that migrated through membranes were fixed with 95%methanol and stained
with 0.1% crystal violet solution (HARLECO, catalog no. 65092A95; EMD Mil-
lipore) for 15 min. Images of the stained cells that migrated to the lower sides
of the filter were captured with an inverted microscope.
ChIP-Seq. ChIP experiments for H3K27ac in T47D cells were performed as
previously described (66), and the antibody for H3K27ac was ab4729
(Abcam). Library construction was performed using the ChIP-seq DNA Sam-
ple Prep Kit (Illumina) according to the manufacturer’s instructions, followed
by high-throughput sequencing with Illumina Hi-Seq.
RNA-Seq. Total RNAs were isolated by TRIzol (Invitrogen), followed by library
construction using the TruSeqRNA Library Prep Kit (Illumina) for IlluminaHi-Seq.
Immunohistochemistry. A total of 47 matched pairs of ER+ breast cancer tu-
mors came from patients treated with tamoxifen, including treatment-naive
primary tumors and local recurrent tumors that developed after tamoxifen
treatment. Details of these tissue samples were previously published (67). The
tissue samples were evaluated on tissue microarrays (TMAs) obtained from
consenting patients at the Royal Marsden Hospital in London. Immunohisto-
chemical staining of CSK was performed on 4-μm sections of TMAs using the
Bond Refine Detection System on a Leica Bond Rx automated immunostainer.
The sections were automatically deparaffinized, and antigen retrieval was
performed with EDTA buffer (pH 9.0) and processed for 20 min. The slides
were incubated with the antibody against CSK (mouse monoclonal, ab54684;
Abcam) at a dilution of 1:50 for 2 h at room temperature. WT MCF7 cell
pellets were used as positive controls, and CSK knockdown MCF7 cell pellets
were used as weak controls. Omission of the primary antibody was used as a
blank control. Immunohistochemistry for CSK showed cytoplasmic staining in
breast cancer cells. To evaluate immunohistochemical expression of CSK on
the TMAs, we utilized a semiquantitative scoring system, whereby stain in-
tensity and percentage of tumor cell positivity were reviewed and scored in a
blinded manner by a pathologist. For each core, we assigned an intensity
score of 0 for negative staining, 1 for weak staining, 2 for moderate staining,
and 3 for strong staining, accompanied by the percentage positivity. CSK in-
dices were calculated by multiplying quantity (0–100%) by intensity (0–3).
Tumor Xenograft Study. The MCF7 cells harboring either gAAVS1 or gCSK
infected with lentiviruses encoding a firefly luciferase (68) were injected s.c.
into the left and right posterior flanks of 5-wk-old, ovariectomized, nude
female mice (Charles River Laboratories) in the presence of estrogen. Mice
were assigned randomly (day 7) to continued estrogen supplementation [E2,
0.1 mg/kg of 17 β-estradiol valerate (Sigma) once a week] or estrogen
withdrawal (−E2). Bioluminescence (BIL) signal was measured once a week,
and tumor volumes were calculated by volume = width2 × length/2. When
the tumor reached ∼150–200 mm3, the mice were randomized for drug
treatments [Veh (10% PEG400/Tween-80/PVP-K30 at a ratio of 90:5:5, 15%
D-α-tocopheryl polyethylene glycol succinate (vitamin E-TPGS), and 75%
hydroxypropylcellulose [0.5%] in 50 mM citrate buffer [pH 3.0]), fulvestrant
(5 mg·wk−1, s.c. [formulated in arachis oil]), and FRAX597 (60 mg/kg, p.o.)].
FRAX597 was formulated in 10% PEG400/Tween-80/PVP-K30 at a ratio of
90:5:5, 15% vitamin E-TPGS, and 75% hydroxypropylcellulose (0.5%) in
50 mM citrate buffer (pH 3.0), and administered by oral gavage. The fold
change in BLI signal was normalized to the first measurement (percentage
relative BIL) when treatments were initiated for each tumor. The duration of
treatment was 28 d for all of the tumor xenografts. The efficacy of FRAX597
and fulvestrant was also assessed in a PDX model of breast cancer that may
better represent the response in patients. Nonobese diabetic/SCID gamma
mice bearing tumor fragments of the TM00386 PDX breast cancer tumor
were sourced from The Jackson Laboratory. The TM00386 PDX model was
derived from an ER+/PR+/HER2− invasive ductal carcinoma. When the tumor
reached ∼150–200 mm3 (80 d postimplantation), mice were randomized into
treatment groups (n = 8 mice per group) and administered Veh [10%
PEG400/Tween-80/PVP-K30 at a ratio of 90:5:5, 15% vitamin E-TPGS, and
75% hydroxypropylcellulose (0.5%) in 50 mM citrate buffer (pH 3.0)], ful-
vestrant (5 mg·wk−1, s.c.), and/or FRAX597 (60 mg/kg, p.o.). FRAX597 was
formulated in 10% PEG400/Tween-80/PVP-K30 at a ratio of 90:5:5, 15% vi-
tamin E-TPGS, and 75% of hydroxypropylcellulose (0.5%) in 50 mM citrate
buffer (pH 3.0). Tumor size and body weight were measured twice per week
throughout the duration of the study (35 d). All mouse experiments were
carried out at the Dana–Farber Cancer Institute Lurie Family Imaging Center.
The animal experiments were carried out under the Lurie Center In-
stitutional Animal Care and Use Committee (IACUC) protocol and were in
accordance with the IACUC standards for the welfare of animals.
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